What is the equity of Nxera Pharma Co this year?
Nxera Pharma Co has equity of 66.81 B JPY this year.
In 2024, Nxera Pharma Co's equity was 66.81 B JPY, a 15.32% increase from the 57.94 B JPY equity in the previous year.
Nxera Pharma Co's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Nxera Pharma Co's equity is essential for assessing its financial health, stability, and value to shareholders.
Evaluating Nxera Pharma Co's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.
Nxera Pharma Co's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.
Fluctuations in Nxera Pharma Co’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.
Nxera Pharma Co has equity of 66.81 B JPY this year.
The equity of Nxera Pharma Co has increased/decreased by 15.32% increased compared to the previous year.
A high equity is advantageous for investors of Nxera Pharma Co as it is an indicator of the company's financial stability and its ability to manage risks and challenges.
A low equity can be a risk for investors of Nxera Pharma Co, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.
An increase in equity of Nxera Pharma Co can strengthen the company's financial position and improve its ability to make investments in the future.
A reduction in equity of Nxera Pharma Co can affect the financial situation of the company and lead to a higher dependence on debt capital.
Some factors that can affect the equity of Nxera Pharma Co include profits, dividend payments, capital increases, and acquisitions.
The equity of Nxera Pharma Co is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.
To change equity, Nxera Pharma Co can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.
Over the past 12 months, Nxera Pharma Co paid a dividend of 2.5 JPY . This corresponds to a dividend yield of about 0.22 %. For the coming 12 months, Nxera Pharma Co is expected to pay a dividend of 0 JPY.
The current dividend yield of Nxera Pharma Co is 0.22 %.
Nxera Pharma Co pays a quarterly dividend. This is distributed in the months of .
Nxera Pharma Co paid dividends every year for the past 0 years.
For the upcoming 12 months, dividends amounting to 0 JPY are expected. This corresponds to a dividend yield of 0 %.
Nxera Pharma Co is assigned to the 'Health' sector.
To receive the latest dividend of Nxera Pharma Co from 6/24/2015 amounting to 10 JPY, you needed to have the stock in your portfolio before the ex-date on 3/27/2015.
The last dividend was paid out on 6/24/2015.
In the year 2023, Nxera Pharma Co distributed 0 JPY as dividends.
The dividends of Nxera Pharma Co are distributed in JPY.
Our stock analysis for Nxera Pharma Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Nxera Pharma Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.